Investigation of Specific Biomarkers in Patients With Atrial Fibrillation Who Undergo Interventional Treatment

Study Overview
=================
Brief Summary
-----------------
The two main mechanisms for atrial fibrillation (AF) recurrence after cryoablation include Pulmonary vein (PV) reconnection and the presence of non-PV associated arrhythmic focuses. The aim of this study is to reveal the specific biomarkers by antibody microarrays.

Detailed Description
-----------------
One hundred twenty patients with atrial fibrillation will participate in the study. They will be divided into three groups. Patients with AF recurrence after the first procedure but with isolated pulmonary veins at the beginning of the second AF ablation b)patients with AF recurrence after repeat PV ablation. Patients with PV-associated atrial fibrillation. The group will be included patients with freedom of atrial fibrillation after PV isolation (first or repeat procedure). Healthy volunteers Groups would be formed from patients who previously underwent atrial fibrillation ablations and whose blood samples have been taken and placed in a biobank before interventional treatment. The first step will include proteomic serum profiling using antibody microarrays in ten subjects will be split into 3 groups. The second step will include validation of selected protein biomarkers, in the total cohort (N=120).

Official Title
-----------------
Investigation of Specific Biomarkers in Patients With Atrial Fibrillation Who Undergo Interventional Treatment

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Diagnostic Test: Proteomic analysis by antibody microarrays


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Patient with paroxysmal/persistent atrial fibrillation who underwent interventional treatment Exclusion Criteria: permanent AF contraindications to oral anticoagulation or heparin chronic kidney disease requiring dialysis untreated hypo- or hyperthyroidism breast feeding pregnancy chronic kidney disease requiring dialysis decompensated heart failure stroke within the last 3 months myocardial infarction within the last 3 months Percutaneous coronary intervention or Coronary Artery Bypass Grafting within the last 3 months active myocarditis artificial valve replacement surgery severe mitral or aortic stenosis coronary artery disease requiring revascularization heart transplant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PV associated atrial fibrillation<br> | Diagnostic Test: Proteomic analysis by antibody microarrays<br>* Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer<br>|
| non-PV associated arrhythmic focuses<br> | Diagnostic Test: Proteomic analysis by antibody microarrays<br>* Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer<br>|
| Healthy volunteers<br> | Diagnostic Test: Proteomic analysis by antibody microarrays<br>* Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| proteins after validation | number of protein which will be specific for non-PV associated arrhythmic focuses group after validation | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| proteins after screening | number of protein which will be specific for non-PV associated arrhythmic focuses group after screening | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atrial fibrillation, protein microarray, proteomic biomarkers, PV dependent atrial fibrillation